CD274 and hepatocellular carcinoma: In particular, the combination of ICIs and VEGF inhibitors shows good results against advanced hepatocellular carcinoma (HCC) [15], and the combination of atezolizumab (anti-PD-L1 antibody) plus bevacizumab (VEGF inhibitor) is now considered a first-line treatment for patients with advanced HCC.